**Table G-16. Results data for dual antiplatelet therapy (aspirin with oral antiplatelet) vs. triple therapy (aspirin with oral anticoagulant and oral antiplatelet): composite and individual outcomes**

| **Study** | **Study Details** | **Outcome(s)** **(Length of Followup)** | **Results reported by authors** |
| --- | --- | --- | --- |
| Buresly, 2005139 | ObservationalTotal N: 21,443Good quality | Primary Composite at 2 yr:Major bleedingMinor bleeding | Warfarin | OR (95% CI): 1.85 (1.54-2.22), reference group ASA |
| ASA + warfarin | OR (95% CI): 1.84 (1.23-2.76), reference group ASA |
| ASA + thienopyridine | OR (95% CI): 1.68 (1.02-2.77), reference group ASA |
| Fosbol, 2012140 | ObservationalTotal N: 7619Fair quality | Primary Composite at 30 days:Total mortalityNonfatal MIStroke | Aspirin | 239/2213 |
| ASA+clopidogrel | 247/2841 |
| Warfarin | 47/563 |
| ASA+warfarin | 90/1271 |
| Triple therapy | 48/731 |
| Primary Composite at 1 yr:Total mortalityNonfatal MIStroke | Aspirin | 808/2213 |
| ASA+clopidogrel | 922/2841 |
| Warfarin | 201/563 |
| ASA+warfarin | 404/1271 |
| Triple therapy | 187/731 |
| Major bleeding at 30 days | Aspirin | 53/2213 |
| ASA+clopidogrel | 85/2841 |
| Warfarin | 15/563 |
| ASA+warfarin | 50/1271 |
| Triple therapy | 30/731 |
| Major bleeding at 1 yr | Aspirin | 223/2213 |
| ASA+clopidogrel | 336/2841 |
| Warfarin | 78/563 |
| ASA+warfarin | 182/1271 |
| Triple therapy | 109/731 |
| Jang, 2011141 | ObservationalTotal N: 362 Poor quality | Primary Composite at 3 yr:Total mortalityNonfatal MIRevascularization | Dual therapy | 43/278 |
| Triple therapy | 10/84 |
| Secondary Composite at 3 yr:Total mortalityNonfatal MIStrokeRevascularizationMajor bleedingMinor bleeding | Dual therapy | 64/278 |
| Triple therapy | 22/84 |
| Total mortality at 3 yr | Dual therapy | 23/278 |
| Triple therapy | 3/84 |
| Nonfatal MI at 3 yr | Dual therapy | 4/278 |
| Triple therapy | 3/84 |
| Revascularization at 3 yr | Dual therapy | 12/278 |
| Triple therapy | 1/84 |
| Stent thrombosis at 3 yr | Dual therapy | 4/278 |
| Triple therapy | 3/84 |
| Major bleeding at 3 yr | Dual therapy | 6/278 |
| Triple therapy | 9/84 |
| Minor bleeding at 3 yr | Dual therapy | 3/278 |
| Triple therapy | 2/84 |
| Stroke at 3 yr | Dual therapy | 12/278 |
| Triple therapy | 1/84 |
| Karjalainen, 2007142 | ObservationalTotal N: 478Good quality | Primary Composite at 1 yr:Total mortalityNonfatal MIRevascularizationStent thrombosis | Triple therapy | 6/219 |
| Dual therapy | 3/227 |
| Secondary Composite at 1 yr:StrokeMajor bleeding | Triple therapy | OR (95% CI): 2.5 (1.2-5.3), reference group dual therapy |
| Stroke at discharge | Triple therapy | 1/219 |
| Dual therapy | 0/227 |
| Major bleeding at discharge | Triple therapy | 4/219 |
| Dual therapy | 0/227 |
| Total mortality at discharge | Triple therapy | 3/219 |
| Dual therapy | 1/227 |
| Nonfatal MI at discharge | Triple therapy | 4/219 |
| Dual therapy | 3/227 |
| Revascularization at discharge | Triple therapy | 3/219 |
| Dual therapy | 1/227 |
| Stent thrombosis at discharge | Triple therapy | 4/219 |
| Dual therapy | 1/227 |
| Stroke at 1 yr | Triple therapy | 7/219 |
| Dual therapy | 5/227 |
| Major bleeding at 1 yr | Triple therapy | 18/219 |
| Dual therapy | 6/227 |
| Total mortality at 1 yr | Triple therapy | 19/219 |
| Dual therapy | 4/227 |
| Nonfatal MI at 1 yr | Triple therapy | 22/219 |
| Dual therapy | 11/227 |
| Revascularization at 1 yr | Triple therapy | 24/219 |
| Dual therapy | 17/227 |
| Stent thrombosis at 1 yr | Triple therapy | 9/219 |
| Dual therapy | 3/227 |
| Konstantino, 2006143 | ObservationalTotal N: 2737Fair quality | Nonfatal MI in-hospital | Dual therapy | 45/2661 |
| Triple therapy | 5/76 |
| Stroke in-hospital | Dual therapy | 15/2661 |
| Triple therapy | 1/76 |
| Major bleeding in-hospital | Dual therapy | 16/2661 |
| Triple therapy | 2/76 |
| Rehospitalization at 30 days | Dual therapy | 445/2661 |
| Triple therapy | 17/76 |
| Total mortality at 30 days | Dual therapy | 29/2661 |
| Triple therapy | 3/76 |
| Total mortality at 6 mo | Dual therapy | 82/2661 |
| Triple therapy | 6/76 |
| Lamberts, 2013144 | ObservationalTotal N: 12,165Good quality | Primary composite at 1 yearTotal mortalityNonfatal MI | Dual therapyTriple therapy | OR (95%CI) 1.17 (0.96-1.42), reference group TT |
| Total mortality | Dual therapyTriple therapy | OR 0.31 (0.24-0.39) Reference group DAPT |
| Stroke | Dual therapyTriple therapy | OR (95%CI) 0.42 (0.28-0.61)Reference group DAPT |
| Lopes, 2010145 | ObservationalTotal N: 23,208 Good quality | Primary Composite at 6 mo:Total mortalityNonfatal MI | Warfarin | OR (95% CI): 0.39 (0.15-0.98), reference group no warfarin (ASA only) |
| Major bleeding in-hospital | Warfarin | 3/124 |
| No warfarin (ASA only) | 6/793 |
| Stroke in-hospital | Warfarin | 2/124 |
| No warfarin (ASA only) | 25/793 |
| Maegdefessel, 2008146 | ObservationalTotal N: 159Fair quality | Major bleeding 1.4 yr | ASA + clopidogrel | 2/103 |
| ASA + Clopidogrel + LMWH | 0/42 |
| ASA + Clopidogrel + OAC | 0/14 |
| Nonfatal MI 1.4 yr | ASA + clopidogrel | 4/103 |
| ASA + Clopidogrel + LMWH | 0/42 |
| ASA + Clopidogrel + OAC | 0/14 |
| Stroke 1.4 yr | ASA + clopidogrel | 9/103 |
| ASA + Clopidogrel + LMWH | 4/42 |
| ASA + Clopidogrel + OAC | 0/14 |
| CV mortality1.4 yr | ASA + clopidogrel | 3/103 |
| ASA + Clopidogrel + LMWH | 5/42 |
| ASA + Clopidogrel + OAC | 1/14 |
| Nguyen, 2007147GRACE Registry | ObservationalTotal N: 800Good quality | Nonfatal MI in-hospital | Triple therapy (ASA + Thienopyridine) | 48/508 |
| Dual therapy (ASA or Thienopyridine) | 26/220 |
| Stroke in-hospital | Triple therapy (Warfarin + ASA + Thienopyridine) | 6/508 |
| Dual therapy ( Warfarin + ASA or Thienopyridine) | 7/220 |
| CHF in-hospital | Triple therapy ( Warfarin + ASA + Thienopyridine) | 128/508 |
| Dual therapy (ASA or Thienopyridine) | 65/220 |
| Major bleeding in-hospital | Triple therapy ( Warfarin + ASA + Thienopyridine) | 34/508 |
| Dual therapy ( Warfarin + ASA or Thienopyridine) | 10/220 |
| Total mortality at 6 mo | Triple therapy ( Warfarin + ASA + Thienopyridine) | 23/453 |
| Dual therapy ( Warfarin + ASA or Thienopyridine) | 12/184 |
| Revascularization at 6 mo | Triple therapy ( Warfarin + ASA + Thienopyridine) | 45/424 |
| Dual therapy ( Warfarin + ASA or Thienopyridine) | 22/176 |
| Stroke at 6 mo | Triple therapy ( Warfarin + ASA + Thienopyridine) | 3/426 |
| Dual therapy (ASA or Thienopyridine) | 6/179 |
| Nonfatal MI at 6 mo | Triple therapy ( Warfarin + ASA + Thienopyridine) | 13/391 |
| Dual therapy ( Warfarin + ASA or Thienopyridine) | 7/154 |
| Persson, 2011148RIKS-HIA and SCAAR | ObservationalTotal N: 27,972Good quality | Primary Composite at 1 yr:Total mortalityNonfatal MI | Triple therapy | RR (95% CI): 1.20 (1.0-1.45), reference group dual therapy |
| Total mortality at 1 yr | Triple therapy | RR (95% CI): 0.82 (0.58-1.16), reference group dual therapy |
| Stroke at 1 yr | Triple therapy | RR (95% CI): 1.60 (1.09-2.34), reference group dual therapy |
| Major bleeding at 1 yr | Triple therapy | RR (95% CI): 1.53 (0.95-2.48), reference group dual therapy |
| Any bleeding at 1 yr | Triple therapy | RR (95% CI): 1.55 (1.08-2.22), reference group dual therapy |
| Rossini, 2008149 | ObservationalTotal N: 102Good quality | Primary Composite at 18 mo:Major bleedingMinor bleeding | Triple therapy | 11/102 |
| Dual therapy | 5/102 |
| Secondary Composite at 18 mo:Total mortalityNonfatal MIStroke | Triple therapy | 6/102 |
| Dual therapy | 5/102 |
| Major bleeding at 18 mo | Triple therapy | 3/102 |
| Dual therapy | 2/102 |
| Minor bleeding at 18 mo | Triple therapy | 8/102 |
| Dual therapy | 3/102 |
| Major bleeding 30 days | Triple therapy | 1/102 |
| Dual therapy | 1/102 |
| Minor bleeding 30 days | Triple therapy | 1/102 |
| Dual therapy | 3/102 |
| Ruiz-Nodar, 2008150 | ObservationalTotal N: 426Good quality | Primary Composite at 5 yr:Total mortalityNonfatal MIRevascularization | Triple therapy | 52/195 |
| Dual therapy | 39/178 |
| Secondary Composite at 5 yr:StrokeMajor bleedingMACE | Triple therapy | 32/195 |
| Dual therapy | 42/178 |
| Total mortality at 5 yr | Triple therapy | 35/195 |
| Dual therapy | 28/178 |
| Nonfatal MI at 5 yr | Triple therapy | 13/195 |
| Dual therapy | 10178 |
| Revascularization at 5 yr | Triple therapy | 14/195 |
| Dual therapy | 8178 |
| Major bleeding at 5 yr | Triple therapy | 29/195 |
| Dual therapy | 9178 |
| Minor bleeding at 5 yr | Triple therapy | 25/195 |
| Dual therapy | 9178 |
| Ruiz-Nodar, 2012151 | ObservationalTotal N: 590Fair quality | Secondary Composite at 1 yr:Total mortalityNonfatal MITarget vessel failure | Coumarin at discharge | HR (95% CI)0.21 (0.08 to 0.57)Reference group no coumarin |
| Total mortality at 1 yr | Coumarin at discharge | HR (95% CI)0.20 (0.06 to 0.64)Reference group no coumarin |
| Major bleeding at 1 yr | Coumarin at discharge | HR (95% CI)2.31 (0.55 to 9.71)Reference group no coumarin |
| Stenestrand, 2005152RIKS-HIA | ObservationalTotal N: 6,275Good quality | Total mortality at 30 days | ASA and/or thienopyridine | 230/3768 |
| OAC +/-platelet inhibitor | 76/1848 |
| Total mortality at 1 yr | ASA and/or thienopyridine | 1183/3768 |
| OAC +/-platelet inhibitor | 414/1848 |

Abbreviations: ASA=aspirin; CHF=congestive heart failure; CI=confidence interval; CV=cardiovascular; HR=hazard ratio; LMWH=low molecular weight heparin; MACE=major adverse cardiac event; MI=myocardial infarction; mo=month/months; N=number of patients; OAC=oral anticoagulation; OR=odds ratio; RR=relative risk; vs=versus; yr=year/years